Latest news with #Vultr
Cision Canada
20-05-2025
- Business
- Cision Canada
Clarifai Joins Vultr Cloud Alliance to Deliver Scalable, Cost-Optimized, Full-Stack AI
WASHINGTON, May 20, 2025 /CNW/ -- Clarifai, a global leader in AI and pioneer of the full-stack AI platform, today announced it has joined the Vultr Cloud Alliance. This collaboration enables enterprises to build, deploy, and scale AI workloads with enhanced flexibility and control over performance, governance, and cost, leveraging Clarifai's platform and Vultr's global high-performance cloud infrastructure. The collaboration brings together Clarifai's full-stack AI platform, which covers everything from model development to deployment and governance, with Vultr's global reach, security, regulatory compliance (including HIPAA, SOC 2+, and more), and operational excellence. Vultr's infrastructure includes high-performance CPUs, managed Kubernetes through Vultr Kubernetes Engine (VKE), managed databases like Apache ® Kafka, scalable storage, bare metal servers, and a wide choice of the latest AMD and NVIDIA GPUs, offering optimal price-to-performance. Together, Clarifai and Vultr offer organizations the ability to run any model in any environment with complete control over performance, governance, and offering up to 90% cost savings. "Combining capabilities with these leading industry partners means customers can now deploy and manage their AI workloads efficiently across Vultr's global cloud, gaining full control over costs and performance while getting access to a broader range of GPUs", said Alfredo Ramos, Chief Product & Technology Officer at Clarifai. "This is about enabling all clouds, all compute, and all AI models on one platform." By working together, joint Clarifai and Vultr customers can save at least 70% on the costs of the NVIDIA A100 80 GB compared to hyperscalers, with potential for greater savings through a longer-term commitment. Customers can purchase single A100 GPUs or in blocks of 8 GPUs. Key highlights of the partnership include: Any AI Model, Any GPU: Users can deploy any open-source, foundation, or custom AI model, including Clarifai's own, across Vultr's extensive GPU lineup, such as AMD Instinct ™ MI300X, MI325X, and NVIDIA HGX ™ B200, HGX ™ H100, A100 PCIe, and L40S. This allows optimization for performance, power efficiency, or cost, supporting AI workloads from inference to fine-tuning. Unified Compute Orchestration: Clarifai's compute orchestration allows deploying any model in a secure, scalable, containerized environment managed via a single interface. Models are deployed across Vultr resources using managed Kubernetes clusters or bare metal servers, with dynamic provisioning and automatic scaling via Vultr Kubernetes Engine (VKE). Built-in governance provides centralized visibility over performance, cost, and access, simplifying AI operations and improving efficiency. Edge AI Capabilities: Clarifai's edge AI platform enables deploying lightweight, high-performance models directly to edge devices, including air-gapped and offline environments. Combined with Vultr's global footprint of 32 data center regions reaching 90% of the global population with low latency (2-40 ms), this delivers real-time intelligence at the data source. This is particularly valuable for use cases like predictive maintenance, industrial quality control, public safety, and content moderation. "Our partnership with Clarifai is exactly what the Vultr Cloud Alliance is all about—bringing together best-of-breed technologies to give customers real choice, real performance, and real value. Clarifai's full-stack AI platform paired with Vultr's global GPU infrastructure means organizations can build and deploy AI models faster, scale efficiently, and reduce cost. It's a practical, high-impact solution for teams looking to take control of their AI workloads—whether in the cloud, at the edge, or across hybrid environments." said Kevin Cochrane, Chief Marketing Officer, Vultr. Joint solutions are applicable across various industries, including: Energy, Aerospace, and Manufacturing: Implement predictive maintenance and improve asset management using AI for visual inspection, edge AI, and global infrastructure. Media and Entertainment: Accelerate AI workloads for content moderation, metadata generation, and asset management on GPU instances. Leverage real-time image, video, and document analysis and state-of-the-art AI models for full motion video and sports analytics. Defense and Public Safety: Deploy AI models for security surveillance, object detection, and domain awareness in secure, air-gapped, or edge environments. Organizations ready to enhance their AI deployments can get started today at preferential pricing. Reserve their GPU cluster via: For more information on the Vultr Cloud Alliance, visit here. About Clarifai Clarifai is a global leader in AI and the pioneer of the full-stack AI lifecycle and orchestration platform that helps organizations create and control AI workloads on any environment with a unified platform. With over a decade of experience supporting millions of custom models and billions of operations for the largest enterprises and governments, Clarifai pioneered compute innovations like custom scheduling, batching, GPU fractioning, and autoscaling. Clarifai empowers users to efficiently run any model, anywhere, at any scale. Learn more at About Vultr Vultr is on a mission to make high-performance cloud infrastructure easy to use, affordable, and locally accessible for enterprises and AI innovators around the world. Vultr is trusted by hundreds of thousands of active customers across 185 countries for its flexible, scalable, global Cloud Compute, Cloud GPU, Bare Metal, and Cloud Storage solutions. Founded by David Aninowsky and self-funded for over a decade, Vultr has grown to become the world's largest privately held cloud infrastructure company. Learn more at
Business Wire
13-05-2025
- Business
- Business Wire
Vultr Deploys New AMD EPYC™ 4005 Series Processors to Deliver Easy-to-Use, Low-Cost Systems for Growing Businesses
WEST PALM BEACH, Fla.--(BUSINESS WIRE)-- Vultr, the world's largest privately-held cloud infrastructure company, today announced that it is one of the first cloud providers to offer the new AMD EPYC™ 4005 Series processors. The AMD EPYC 4005 Series processors will be available on the Vultr platform, enabling enterprise-class features and leading performance for businesses and hosted IT service providers. The AMD EPYC 4005 Series processors extend the broad AMD EPYC processor family, powering a new line of cost-effective systems designed for growing businesses and hosted IT services providers that demand performance, advanced technologies, energy efficiency, and affordability. Servers featuring the high-performance AMD EPYC 4005 Series CPUs with streamlined memory and I/O feature sets are designed to deliver compelling system price-to-performance metrics on key customer workloads. Meanwhile, the combination of up to 16 SMT-capable cores and DDR5 memory in the AMD EPYC 4005 Series processors enables smooth execution of business-critical workloads, while maintaining the thermal and power efficiency characteristics crucial for affordable compute environments. 'Vultr is committed to delivering the most advanced cloud infrastructure with unrivaled price-to-performance,' said J.J. Kardwell, CEO of Vultr. 'The AMD EPYC 4005 Series provides straightforward deployment, scalability, high clock speed, energy efficiency, and best-in-class performance. Whether you are a business striving to scale reliably or a developer crafting the next groundbreaking innovation, these solutions are designed to deliver exceptional value and meet demanding requirements now and in the future.' Vultr's launch of systems featuring the AMD EPYC 4245P and AMD EPYC 4345P processors will expand the company's robust line of Bare Metal solutions. Vultr will also feature the AMD EPYC 4345P as part of its High Frequency Compute (HFC) offerings for organizations requiring the highest clock speeds and access to locally-attached NVMe storage. 'We designed the AMD EPYC 4005 Series CPUs with our system partners in mind, creating a processor that enables them to develop differentiated, cost-effective enterprise solutions,' said Derek Dicker, Corporate Vice President, Enterprise and HPC Business, AMD. 'The memory and I/O feature sets, combined with our latest 'Zen 5' architecture, give our technology partners the flexibility to create powerful yet affordable systems that meet the specific needs of growing businesses and dedicated hosters.' AMD is a member of the Vultr Cloud Alliance, a composable ecosystem of best-of-breed technology partners delivering integrated solutions and services for cloud computing. The AMD EPYC 4005 Series joins Vultr's other AMD offerings, which include the AMD EPYC 9004 Series, the AMD EPYC 7003 Series, and the AMD Instinct MI325X and MI300X GPUs. To learn more about the AMD and Vultr partnership, visit us here and contact sales to get started. About Vultr Vultr is on a mission to make high-performance cloud infrastructure easy to use, affordable, and locally accessible for enterprises and AI innovators around the world. Vultr is trusted by hundreds of thousands of active customers across 185 countries for its flexible, scalable, global Cloud Compute, Cloud GPU, Bare Metal, and Cloud Storage solutions. Founded by David Aninowsky and self-funded for over a decade, Vultr has grown to become the world's largest privately held cloud infrastructure company. Learn more at:
National Post
13-05-2025
- Business
- National Post
Vultr Deploys New AMD EPYC™ 4005 Series Processors to Deliver Easy-to-Use, Low-Cost Systems for Growing Businesses
Article content Article content WEST PALM BEACH, Fla. — Vultr, the world's largest privately-held cloud infrastructure company, today announced that it is one of the first cloud providers to offer the new AMD EPYC™ 4005 Series processors. The AMD EPYC 4005 Series processors will be available on the Vultr platform, enabling enterprise-class features and leading performance for businesses and hosted IT service providers. Article content The AMD EPYC 4005 Series processors extend the broad AMD EPYC processor family, powering a new line of cost-effective systems designed for growing businesses and hosted IT services providers that demand performance, advanced technologies, energy efficiency, and affordability. Servers featuring the high-performance AMD EPYC 4005 Series CPUs with streamlined memory and I/O feature sets are designed to deliver compelling system price-to-performance metrics on key customer workloads. Meanwhile, the combination of up to 16 SMT-capable cores and DDR5 memory in the AMD EPYC 4005 Series processors enables smooth execution of business-critical workloads, while maintaining the thermal and power efficiency characteristics crucial for affordable compute environments. Article content 'Vultr is committed to delivering the most advanced cloud infrastructure with unrivaled price-to-performance,' said J.J. Kardwell, CEO of Vultr. 'The AMD EPYC 4005 Series provides straightforward deployment, scalability, high clock speed, energy efficiency, and best-in-class performance. Whether you are a business striving to scale reliably or a developer crafting the next groundbreaking innovation, these solutions are designed to deliver exceptional value and meet demanding requirements now and in the future.' Article content Vultr's launch of systems featuring the AMD EPYC 4245P and AMD EPYC 4345P processors will expand the company's robust line of Bare Metal solutions. Vultr will also feature the AMD EPYC 4345P as part of its High Frequency Compute (HFC) offerings for organizations requiring the highest clock speeds and access to locally-attached NVMe storage. Article content 'We designed the AMD EPYC 4005 Series CPUs with our system partners in mind, creating a processor that enables them to develop differentiated, cost-effective enterprise solutions,' said Derek Dicker, Corporate Vice President, Enterprise and HPC Business, AMD. 'The memory and I/O feature sets, combined with our latest 'Zen 5' architecture, give our technology partners the flexibility to create powerful yet affordable systems that meet the specific needs of growing businesses and dedicated hosters.' Article content AMD is a member of the Vultr Cloud Alliance, a composable ecosystem of best-of-breed technology partners delivering integrated solutions and services for cloud computing. The AMD EPYC 4005 Series joins Vultr's other AMD offerings, which include the AMD EPYC 9004 Series, the AMD EPYC 7003 Series, and the AMD Instinct MI325X and MI300X GPUs. Article content Vultr is on a mission to make high-performance cloud infrastructure easy to use, affordable, and locally accessible for enterprises and AI innovators around the world. Vultr is trusted by hundreds of thousands of active customers across 185 countries for its flexible, scalable, global Cloud Compute, Cloud GPU, Bare Metal, and Cloud Storage solutions. Founded by David Aninowsky and self-funded for over a decade, Vultr has grown to become the world's largest privately held cloud infrastructure company. Article content Article content Article content Contacts Article content Article content
Time Business News
09-05-2025
- Business
- Time Business News
Cloudways Review 2025:What's New in Cloudways Hosting? Full Review
If you've been dealing with hosting nightmares, endlessly juggling cPanel, getting lost in server configurations, or worrying about your site going down during traffic spikes, you're not alone. Hosting is supposed to be simple, reliable, and fast. That's where Cloudways steps in and honestly, it feels like it was built for people like us – service providers, freelancers, developers, agencies, and even non-tech-savvy entrepreneurs. This is not your usual tech-heavy review. No jargons, no complexity. Just an honest experience of what Cloudways offers in 2025 and why more and more people are switching to it. When you first log into Cloudways, it immediately feels different. The dashboard is modern, clean, and makes launching servers or applications feel like a walk in the park. You choose your cloud provider – DigitalOcean, Vultr, AWS, Google Cloud or Linode. Then you pick the server size that fits your project and boom, you're live. No need to go through complicated server commands or confusing panels. It's all visual, smooth, and just works. What makes Cloudways insanely fast? The secret lies in its custom-built ThunderStack. It combines powerful components like: NGINX + Apache : The two work together to serve dynamic and static content efficiently. : The two work together to serve dynamic and static content efficiently. Varnish Cache : Speeds up page loads up to 10 times for cloud-hosted websites. : Speeds up page loads up to 10 times for cloud-hosted websites. Memcached + Redis : For database-driven sites, these reduce server load and improve performance. : For database-driven sites, these reduce server load and improve performance. PHP-FPM and PHP 8 : These ensure smooth and fast PHP execution. And yes, you can switch between PHP 7.4, 8.0, 8.2, and 8.3 with a click. : These ensure smooth and fast PHP execution. And yes, you can switch between PHP 7.4, 8.0, 8.2, and 8.3 with a click. MySQL / MariaDB: You get the choice. Most users prefer MariaDB 10.6 for its stability and speed. All this makes your WordPress, WooCommerce, Laravel, or custom PHP apps load significantly faster than typical shared hosting platforms. This is where Cloudways really outshines most managed hosting services. With Cloudflare Enterprise integrated, you're getting the kind of protection and performance previously reserved for large-scale businesses. Here's what you get: Fastest CDN with over 200 global locations with over 200 global locations Image Optimization for faster load times for faster load times Mobile Optimization to serve content based on device to serve content based on device Edge Page Caching for lightning-fast delivery for lightning-fast delivery DDoS Protection and Managed WAF for rock-solid security And you don't have to set up anything manually. Just enable it, and you're done. Cloudways gives you full control over your stack. Want to switch between PHP versions? Do it with a dropdown. Need the latest MariaDB version? You got it. The flexibility is unmatched, especially for developers and agencies who manage multiple types of applications. Security is often made overly technical, but Cloudways makes it simple. With their built-in firewall controls, you can whitelist or block IPs, manage TTLs, and even monitor access history. This kind of control is rare in managed hosting, and it makes you feel like you're in charge without needing to be a cybersecurity expert. Cloudways has introduced some powerful updates that make it more practical and user-friendly than ever: Bulk Domain Management : Add multiple domains to an app in one go. : Add multiple domains to an app in one go. MyDumper Backup Utility : Back up large databases in a fraction of the time. : Back up large databases in a fraction of the time. SafeUpdates with Health Check : Updates are now smarter. They won't run if your app is in a broken state. : Updates are now smarter. They won't run if your app is in a broken state. Redesigned Migration Experience : Moving to Cloudways is now a breeze with their full-page migration interface. : Moving to Cloudways is now a breeze with their full-page migration interface. PHP 8.3 Availability : Get the latest performance benefits instantly. : Get the latest performance benefits instantly. Bandwidth Usage Insights: Especially useful for AWS and Google Cloud users to monitor and control costs. These are not just technical upgrades. They solve real user problems. Need help? The Cloudways Knowledgebase is loaded with step-by-step guides and video tutorials. From billing to advanced server tuning, it's all there. And if you get stuck, their 24/7 live chat support is actually helpful. Not just bot replies. Real humans who know the platform. You only pay for what you use. Plans start as low as $14/month for DigitalOcean servers, and you can scale up or down anytime. There's also a 3-day free trial to test things out before you commit. No credit card required. Absolutely. Whether you're a solo entrepreneur managing a portfolio site, an agency with dozens of client projects, or a SaaS builder, Cloudways meets you where you are and grows with you. It's fast, flexible, secure, and most importantly, human-friendly. If you're tired of traditional hosting panels and unreliable support, give Cloudways a shot. It's hosting without the headache. Try Cloudways for Free Visit and start your 3-day free trial. TIME BUSINESS NEWS
Yahoo
28-03-2025
- Business
- Yahoo
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. AUSTIN, Texas, March 28, 2025--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug discovery sector, our recent milestones underscore the growing recognition of our innovative AI and growth potential. Notably, we've secured a strategic partnership valued at $8-10 million USD with a leading biotech company, leveraging our proprietary B-cell Select technology and AI-driven capabilities to enhance our development and optimization processes. These AI-driven development and optimization capabilities are accelerating the advancement of novel therapies, positioning us at the forefront of innovation. Our collaborations with Vultr, AMD and other Leading Providers of Advanced GPU technologies further enhance our lab-in-a-loop drug discovery and development capabilities, not only driving cost-effectiveness for our pharma partners but also increasing our competitiveness in securing future collaborations. This strategic alignment is positively impacting both our top line and gross profit margins in the AI sector, as we continue to drive robust growth and expand our presence in the rapidly evolving AI healthcare landscape. We are excited about the potential of these current partnerships and looks forward to forming new collaborations that will further accelerate our mission to transform the future of healthcare through AI-driven innovation," stated Dr. Jennifer Bath, President and CEO. "While BioStrand's AI revenue currently represents a modest portion of our total topline, it stands out for its remarkably high gross margins—exceeding 90% in recent quarters, a level of profitability that is truly exceptional in our industry. This positive dynamic reveals one of the most important yet underappreciated financial drivers of our business: as AI revenues scale, so does the path to profitability at an accelerated pace. Unlike traditional project-based services, IPA's AI-driven offerings generate significant leverage and recurring value, creating a robust foundation for sustainable growth. This margin profile—combined with accelerating adoption—positions IPA's AI segment as a powerful engine for long-term shareholder value and a key catalyst for our future success," stated Joseph Scheffler, Interim CFO. Third Quarter Corporate Update and Recent Business Highlights Entered into a USD $8M–$10M partnership with a USD $3 billion market cap global biotechnology company to co-develop Antibody-Drug Conjugates (ADCs) and bispecific antibodies, reinforcing demand for IPA's B-Cell and AI-powered platforms. Expanded AI infrastructure through strategic collaborations with Vultr, AMD and other leading providers of advanced GPU technologies enabling high-performance GPU computing for generative AI. Corporate headquarters relocated to Austin, Texas: Expanding IPA's U.S. footprint in the heart of a thriving AI, biotech, and semiconductor ecosystem. This strategic move takes advantage of Texas's zero corporate income tax, allowing us to reinvest savings in business expansion and innovation. Additionally, the state's robust economy and skilled workforce will support our growth ambitions, positioning us for increased competitiveness and profitability in the rapidly evolving AI healthcare landscape. Resilience in Challenging Market Conditions: Our year-to-date revenue stability and high margin profile, including BioStrand's 131.8% year-over-year revenue growth and 97% gross margin, underscore IPA's solid financial position and ability to navigate difficult market conditions effectively. Announced key leadership changes, including the appointment of Joseph Scheffler as Interim CFO and Kamil Isaev to the Board of Directors, enhancing financial oversight and business strategy. Completed a USD $8.8 million At-the-Market (ATM) equity raise and announced the full conversion of the Yorkville debenture, strengthening IPA's balance sheet and removing near-term convertible debt. Pioneered AI-designed GLP-1 therapeutics for diabetes and metabolic disorders, using unique nucleic acid-based delivery technology and the LENSai™ platform to enhance efficacy, safety, and patient compliance. Realigned pipeline strategy, launching a new AI-powered therapeutic development pipeline driven by first principles thinking and proprietary machine learning models. Revealed multiple ADC lead candidates with demonstrated tumor-killing capabilities, potentially positioning IPA in the high-growth $20B antibody-drug conjugate market. Insider Confidence Reinforced: Key members of IPA's leadership and BioStrand co-founders acquired 763,120 shares on the open market—an aggregate investment of USD $306,000—demonstrating strong internal conviction in the Company's long-term strategy and AI-driven growth trajectory. Third Quarter FY25 Financial Results Revenue: Total revenue was $6.2 million, compared to revenue of $6.2 million in fiscal year 2024 ("FY24") Q3. Project revenue generated $5.6 million, including projects using IPA's proprietary B Cell Select® platform and IPA's proprietary LENSai platform, compared to $5.8 million in FY24 Q3. Product sales and cryostorage revenue were $0.6 million, compared to $0.4 million in FY24 Q3. Research & Development (R&D) Expenses: R&D expenses were $1.1 million, compared to $1.0 million in FY24 Q3, reflecting increased salary and benefits related to the build of the Company's LENSai platform. Sales & Marketing (S&M) Expenses: S&M expenses were $1.3 million, compared to $0.6 million in FY24 Q3 and includes S&M expenses related to social media and digital campaigns. S&M costs related to BioStrand LENSai. General & Administrative (G&A) Expenses: G&A expenses were $3.6 million, compared to $4.2 million in FY24 Q3. Impairment: The Company recorded an impairment charge of $21.2 million related to BioStrand's intangible assets. This adjustment reflects a delay in expected cash flows and resulted in full impairment of the remaining intangible assets after the Company recorded an impairment charge of $15.0 million related to BioStrand in fiscal 2024. Despite this change in valuation, IPA remains committed to its strategic investments and long-term growth plans. Net Loss: Net loss of $21.5 million, or $(0.66) per share on a basic and diluted basis, as compared to a net loss of $2.7 million or $(0.10) on a basic and diluted basis in FY24 Q3. Liquidity: Cash totaled $12.9 million as of January 31, 2025, compared to $3.5 million as of April 30, 2024. *All financial figures are in Canadian Dollars (CAD) unless otherwise stated. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at ***Participant Dial-In Details*** Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name. USA / International Toll +1 (646) 307-1963USA - Toll-Free (800) 715-9871Canada - Toll-Free (800) 715-9871 ***Webcast Details*** Attendee URL: Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at and including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family"). For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. These statements reflect the Company's expectations, plans, projections, and beliefs regarding future events or performance. Words such as "expects," "anticipates," "intends," "believes," "plans," "potential," "will," "may," "continue," and variations thereof are intended to identify forward-looking statements. Forward-looking statements in this release include, but are not limited to, statements related to the Company's operational and financial outlook, the potential impact and continuity of strategic partnerships, including the recently announced commercial agreement and collaborations with cloud infrastructure providers, our projected growth in AI-driven revenues and margins, our ability to commercialize new technologies such as de novo antibody design and AI-designed GLP-1 therapeutics, future demand for our platform capabilities, ongoing strategic initiatives including business realignment and divestitures, and our ability to drive sustainable profitability. These statements are based on management's current expectations and assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. These include, but are not limited to: execution risks related to strategic partnerships, delays or failures in technology development or commercialization, market adoption of AI-based drug discovery tools, fluctuations in financial markets, general economic conditions, and risks related to funding requirements and liquidity. The Company cautions readers not to place undue reliance on these forward-looking statements. All such statements are made as of the date of this release and, unless required by law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. For a complete discussion of risk factors, investors should refer to IPA's filings with Canadian and U.S. securities regulators, including the most recent Annual Report on Form 20-F available at and IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited - Expressed in Canadian dollars) Three months endedJanuary 31, Nine months endedJanuary 31, (in thousands, except share data) Note 2025$ 2024$ 2025$ 2024$ REVENUE 6,151 6,221 17,539 18,059 COST OF SALES 2,856 3,024 8,451 9,114 GROSS PROFIT 3,295 3,197 9,088 8,945 EXPENSES Research and development 1,057 1,001 3,854 2,783 Sales and marketing 1,310 649 3,265 2,633 General and administrative 3,594 4,178 11,029 11,473 Amortization of intangible assets 6 623 709 1,842 2,267 Asset Impairment 6 21,184 — 21,184 — 27,768 6,537 41,174 19,156 Loss before other income (expenses) and income taxes (24,473 ) (3,340 ) (32,086 ) (10,211 ) OTHER INCOME (EXPENSES) Accretion (3 ) (5 ) (8 ) (15 ) Grant income 13 (4 ) — 164 300 Interest and other income (expense) (169 ) 3 (286 ) 26 Unrealized foreign exchange gain (loss) 114 (115 ) (151 ) 21 (62 ) (117 ) (281 ) 332 Loss before income taxes (24,535 ) (3,457 ) (32,367 ) (9,879 ) Income taxes 2 3,014 778 4,294 1,374 NET LOSS FOR THE PERIOD (21,521 ) (2,679 ) (28,073 ) (8,505 ) OTHER COMPREHENSIVE INCOME (LOSS) Items that will be reclassified subsequently to loss Exchange difference on translating foreign operations (142 ) (402 ) 546 (1,110 ) COMPREHENSIVE LOSS FOR THE PERIOD (21,663 ) (3,081 ) (27,527 ) (9,615 ) LOSS PER SHARE – BASIC AND DILUTED (0.66 ) (0.10 ) (0.96 ) (0.34 ) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 32,851,233 25,800,919 29,367,687 25,298,660 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited - Expressed in Canadian dollars) (in thousands) Note January 31,2025$ April 30,2024$ ASSETS Current assets Cash 12,915 3,459 Amounts receivable, net 3,606 3,790 Tax receivable 177 414 Inventory 1,920 2,139 Unbilled revenue 1,082 277 Prepaid expenses 1,042 1,408 20,742 11,487 Restricted cash 90 86 Deposit on equipment 488 475 Property and equipment 5, 8 15,219 16,696 Intangible assets 6 1,124 23,557 Goodwill 7,871 7,687 Total assets 45,534 59,988 LIABILITIES Current liabilities Accounts payable and accrued liabilities 11 4,391 4,372 Deferred revenue 2,353 1,353 Income taxes payable 2 202 553 Leases 8 1,689 1,563 Deferred acquisition payments 298 284 Debentures, net 7 — — 8,933 8,125 Leases 8 11,239 12,118 Deferred income tax liability 238 4,067 Total liabilities 20,410 24,310 SHAREHOLDERS' EQUITY Share capital 9 136,354 119,773 Contributed surplus 9 12,779 12,387 Accumulated other comprehensive loss 2,624 2,078 Accumulated deficit (126,633 ) (98,560 ) 25,124 35,678 Total liabilities and shareholders' equity 45,534 59,988 IMMUNOPRECISE ANTIBODIES LTD. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS For the nine months ended January 31, 2025 and 2024 (Unaudited - Expressed in Canadian dollars) (in thousands) Note 2025$ 2024$ Operating activities: Net loss for the period (28,073 ) (8,505 ) Items not affecting cash: Amortization and depreciation 5, 6, 14 4,206 4,156 Deferred income taxes (3,935 ) (1,209 ) Accretion 8 15 Foreign exchange 159 118 Gain on investment (7 ) (21 ) Share-based expense 9, 10, 11 392 1,298 Asset Impairment 21,184 — (6,066 ) (4,148 ) Changes in non-cash working capital related to operations: Amounts receivable 306 439 Inventory 253 (513 ) Unbilled revenue (759 ) (416 ) Prepaid expenses 388 184 Accounts payable and accrued liabilities 11 (87 ) 1,462 Sales and income taxes payable and receivable (298 ) 339 Deferred revenue 993 1,050 Net cash used in operating activities (5,270 ) (1,603 ) Investing activities: Purchases of property and equipment 5 (440 ) (270 ) Security deposit on leases — (157 ) Deferred acquisition payments — (146 ) Sale of QVQ Holdings BV shares — 121 Net cash used in investing activities (440 ) (452 ) Financing activities: Proceeds on share issuance, net of transaction costs 9 12,211 935 Repayment of leases 8 (1,142 ) (1,037 ) Proceeds on debenture issuance, net of transaction costs 7 4,242 — Net cash provided by (used in) financing activities 15,311 (102 ) Increase (decrease) in cash during the period 9,601 (2,157 ) Foreign exchange (141 ) 80 Cash – beginning of the period 3,545 8,366 Cash – end of the period 13,005 6,289 Cash is comprised of: Cash 12,915 6,204 Restricted cash 90 85 13,005 6,289 Cash paid for interest — — Cash paid for income tax — — View source version on Contacts Investor Relations Contact investors@
